Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children
Status:
Suspended
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the safety and pharmacokinetics (single- and
multiple-dose) of oxymorphone ER for the relief of moderate to severe pain in pediatric
participants ages 7 - ≤17 years old requiring a continuous, around-the-clock (ATC) opioid
treatment for an extended period.